Diaceutics PLC Notice of Results & Presentations
September 09 2024 - 1:00AM
RNS Regulatory News
RNS Number : 2990D
Diaceutics PLC
09 September 2024
Diaceutics - Notice of
Results & Presentations
Belfast and
London, 9 September 2024 -
Diaceutics PLC
(AIM: DXRX), a leading technology and
solutions provider to the pharma and biotech
industry, will announce its
unaudited results for the half year ended 30 June
2024 on Tuesday, 17 September 2024.
Analyst Presentation:
A webinar presentation for analysts
and investors will be held at 1330 BST
(0830 ET) on Tuesday, 17 September 2024. Those wishing to attend can register
using the following link:
https://sparklive.lseg.com/Diaceutics/events/30b6a0fa-97bd-4e8e-b03e-69b2ee50e3ea/diaceutics-h1-2024-results-analyst-investor-call
Investor Meet Presentation:
A webinar presentation for
investors will be held via the Investor
Meet platform at 1630 BST (1130 ET) on Tuesday, 17 September
2024. The presentation is open to all
existing and potential shareholders and registration can be
completed via the following link:
https://www.investormeetcompany.com/diaceutics-plc/register-investor
Questions can be submitted pre-event
via your Investor Meet Company dashboard up until 0900 BST the day
before the meeting or at any time during the live presentation.
Investors who already follow Diaceutics on the Investor Meet
Company platform will automatically be invited.
Enquiries:
Diaceutics
PLC
|
|
Ryan Keeling, Chief Executive
Officer
Nick Roberts, Chief Financial
Officer
|
Tel: +44 (0)28 9040 6500
investorrelations@diaceutics.com
|
|
|
Canaccord
Genuity Limited (Nomad &
Broker)
|
Tel: +44 (0)20 7523 8000
|
Simon Bridges, Andrew Potts, Harry
Rees
|
|
Alma Strategic
Communications
|
Tel: +44(0)20 3405 0205
|
Caroline Forde, Kinvara Verdon
|
diaceutics@almastrategic.com
|
About Diaceutics
At Diaceutics we believe that every
patient should get the opportunity to receive the right test and
the right therapy to positively impact their disease
outcome. We provide the world's leading
pharma and biotech companies with an end-to-end commercialisation
solution for precision medicines through data analytics, scientific
and advisory services enabled by our platform DXRX - The
Diagnostics Network ®.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact
rns@lseg.com or visit
www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our
Privacy
Policy.
END
NORUPUGCBUPCGCQ
Diaceutics (LSE:DXRX)
Historical Stock Chart
From Oct 2024 to Nov 2024
Diaceutics (LSE:DXRX)
Historical Stock Chart
From Nov 2023 to Nov 2024